Capecitabine in advanced hepatocellular carcinoma

Dig Liver Dis. 2016 Oct;48(10):1260-1. doi: 10.1016/j.dld.2016.06.037. Epub 2016 Jul 18.

Authors

Francesca Murer¹, Caterina Pozzan¹, Giulia Peserico¹, Fabio Farinati²

Affiliations

¹ Department of Surgery, Oncology and Gastroenterology, University Policlinic, University of Padua, Padua, Italy.
² Department of Surgery, Oncology and Gastroenterology, University Policlinic, University of Padua, Padua, Italy. Electronic address: [email protected].

PMID: 27476466
DOI: 10.1016/j.dld.2016.06.037

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / administration & dosage*
Antimetabolites, Antineoplastic / adverse effects
Capecitabine / administration & dosage*
Capecitabine / adverse effects
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / pathology
Female
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Male
Middle Aged
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use*
Sorafenib
Survival Analysis

Substances

Antimetabolites, Antineoplastic
Phenylurea Compounds
Niacinamide
Capecitabine
Sorafenib